SAN FRANCISCO--(BUSINESS WIRE)--Carmot Therapeutics announced today that Dave Jobes, PhD, has joined the company as vice president of business development.
Dr. Jobes brings nearly 15 years of biopharmaceutical industry experience to Carmot from such diverse areas as diagnostics, vaccines, and small molecule therapeutics. Prior to joining Carmot, he successfully headed his own consulting firm focused on assisting clients with transactional work and business development strategies. Previously, he was co-founder and vice president of business development at Presidio Pharmaceuticals, a small molecule antiviral company. Dr. Jobes has also served in various research and leadership roles at VaxGen, Applied Biosystems, and the National Institutes of Health (NIH). Dr. Jobes will be leading Carmot’s partnering efforts around its internal programs in diabetes and cancer, its proprietary lead-identification technology, Chemotype Evolution, and Tethering, to which Carmot has an exclusive license.
“We are pleased to welcome Dave to Carmot as we continue to rapidly expand our partnering efforts around Chemotype Evolution and our internal pipeline of GLP-1 agonists and anti-cancer drug molecules,” stated Stig Hansen, PhD, CEO of Carmot. “Dave’s extensive deal-making background is an excellent fit for the company as we continue to grow through partnerships and collaborations.”
“Carmot has pioneered a truly innovative means of rapidly identifying new small molecule leads for challenging drug targets, and now is an exciting time to join the company,” commented Dr. Jobes. “Building on the recently announced collaboration with Amgen, we expect to continue to generate significant interest in both Chemotype Evolution as well as our robust internal pipeline. In addition, Carmot is now offering academic and commercial licenses to Tethering, a powerful methodology for probing protein function by covalent modification of cysteine residues.”
Carmot Therapeutics, Inc. is pioneering a transformative lead-identification technology, Chemotype Evolution, to identify superior therapeutics for human diseases. The technology provides rapid access to novel, target-relevant chemical diversity, thereby addressing important unmet chemical needs. Moreover, Chemotype Evolution can identify small molecules with functional properties of much larger peptides, a challenging goal in drug discovery. Carmot is applying Chemotype Evolution to identify leads for difficult protein-protein interactions and GPCR targets in metabolic disease, oncology, and inflammation. Carmot is further exploiting Chemotype Evolution by working with industry partners on targets of mutual interest. Carmot also holds an exclusive license to intellectual property covering Tethering, including issued US patents 6,335,155, 6,811,966, 6,919,178, 6,998,233, 7,202,033, and 7,214,487.